Pharmacy Policy Bulletin

Title: Quantity Level Limits for Pharmaceuticals Covered Under the Prescription Drug Benefit

Policy #: Rx.01.76

Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract. Some medications may be subject to precertification, age, quantity, or formulary restrictions (ie limits on non-preferred drugs). Individual member benefits must be verified.

This pharmacy policy document describes the status of pharmaceutical information and/or technology at the time the document was developed. Since that time, new information relating to drug efficacy, interactions, contraindications, dosage, administration routes, safety, or FDA approval may have changed. This Pharmacy Policy will be regularly updated as scientific and medical literature becomes available. This information may include new FDA-approved indications, withdrawals, or other FDA alerts. This type of information is relevant not only when considering whether this policy should be updated, but also when applying it to current requests for coverage.

Members are advised to use participating pharmacies in order to receive the highest level of benefits.

Intent:

The intent of this policy is to communicate the medical necessity criteria for medications that have quantity limits as provided under the member's prescription drug benefit. Applicable medications may not be appropriate for members when prescribed in quantities above quantity level limits. Quantities exceeding the quantity level limits may create safety concerns or inappropriate utilization issues. Medications subject to quantity level limits are reviewed by the Pharmacy and Therapeutics (P&T) Committee.

Description:

Quantity limits are designed to allow a sufficient supply of medication based upon FDA-approved or medically accepted maximum daily doses and length of therapy of a particular drug. Quantity limits may be expressed as quantity over time or maximum daily dose. Additionally, there are some medications to which a limit on the days' supply is applied.

A. Quantity over time: This quantity limit is based on dosing guidelines over a rolling time period, usually 30 days.
B. Maximum daily dose (maximum quantity per day): This quantity limit is based on maximum number of units of the drug allowed per day.
C. Days' supply limit: This limits the numbers of days of therapy in a defined time period. Maximum daily dose applies to days' supply limits.

Refer to the specific manufacturer's prescribing information for additional details.

Quantity limits for opioids are included in the opioid policy.

Quantity limits apply to some drugs to achieve dose optimization, which is a utilization management strategy that encourages consolidation of medication regimen to the lowest number of units when medically appropriate. The goal of dose optimization is to reduces pill burden and waste. Exceptions may be made when medical necessity is established such as dose titration, inability to swallow larger pills or the requested dose is not commercially available. For example, when a medication is available in tablets of 10mg and 20mg strengths, with a maximum dose 20mg per day; the quantity limit in place will favor the 20mg tablet once daily over two tablets of the 10mg strength once daily. However, if the individual is unable to swallow the 20mg tablet due to its size; an exception may be made to allow two tablets of the

10mg strength per day.

Policy:

General quantity limit criteria

Quantity limit requests are approved when ONE of the following is met: (drug specific criteria below).

a. Requests that exceed the cumulative daily maximum dose, maximum dose frequency, or maximum duration of therapy approved by the FDA or as stated in accepted compendia[1] are considered off-label and are reviewed per Off-Label Use policy, OR
b. Requests that do not exceed the cumulative daily maximum dose, maximum dose frequency or maximum duration of therapy approved by the FDA or as stated in accepted compendia[1]: A quantity limit exceeding those listed in the following table is approved when ONE of the following is met:
    I. Documentation of the inability to reach the requested dose with higher strengths of commercially available dosage forms due to member specific characteristics (i.e, inability to swallow larger pills, malabsorption, presence of a feeding tube, etc); OR
    II. The requested dose is not commercially available;

OR

c. Requests that do not have a cumulative daily maximum dose, maximum dose frequency or maximum duration of therapy approved by the FDA or as stated in accepted compendia[1]: A quantity limit exceeding those listed in the following table is approved when there is documentation of medical necessity.

[1] Please refer to the Off-Label Use policy for definition of accepted compendia

Drug specific quantity limit criteria:

Icatibant (Firazyr®) specific criteria:

A quantity limit exceeding those listed is approved when BOTH of the following criteria are met:

1. The total dose does not exceed FDA approved maximum dose; and

2. ONE of the following:

a. For Hereditary Angioedema (HAE)Types I and II: documentation of an inadequate response or inability to tolerate C1 inhibitor replacement therapy (e.g., Cinryze®, Berinert®); or

b. For HAE non-Type I or II: documentation of medical necessity

Migraine Agents specific criteria:

An increased quantity of a migraine agent is approved when there is a diagnosis of migraine headache and all of the following inclusion criteria are met:

1. Trial of prophylactic treatment with one of the following: beta blocker, calcium channel blocker, tricyclic antidepressant, valproic acid, cyproheptadine or topiramate; and

2. Requested quantity does not exceed the manufacturer-recommend maximum doses; and

3. The individual has been examined by a neurologist within the past three years.

Proton pump inhibitor specific criteria:

Increased quantity limits of proton pump inhibitors are approved when ONE of the following is met:

1. Pathological hypersecretory condition including Zollinger-Ellison syndrome; or

2. Barrett's esophagus; or

3. Upper gastrointestinal bleed (gastric or duodenal); or

4. Failure of once daily proton pump inhibitor therapy with ONE of the following:

    a. Gastroesophageal reflux disease (GERD) with nocturnal symptoms; or

    b. GERD or erosive esophagitis for member less than 11 years old; or

    c. Laryngopharyngeal reflux; or

    d. Treatment for the eradication of H pylori with triple therapy (duration of therapy will be limited to 14 days)

Smoking Cessation Agents specific criteria:

Additional days' supply of bupropion (Zyban®), Varenicline (Chantix®) and Nicotine Replacements (Nicotine gum, patches, inhalers, and spray) are approved when all the following are met:

1. One month has passed since last failure; and

2. Member is enrolled in a Smoking Cessation Program (in person or online); and

3. Member is currently a smoker

Authorization length: 6 months

Epinephrine pens/ auto-injectors

A quantity limit exceeding those listed may be considered with documentation that a member needs an additional supply based on medical necessity (where additional doses or storage at additional locations are required).
Authorization length: 6 months

Black Box Warning:

ADHD Agents

Adzenys XR-ODT™, Adzenys ER®, Adderall®, Adderall® XR, Dyanavel® XR, Dexedrine®, Dextroamphetamine sulfate, ProCentra®, Zenzedi™, Vyvanse®, Aptensio XR™, QuilliChew ER™, Quillivant XR®

A. Abuse and dependence: CNS stimulants, other amphetamine-containing products, and methylphenidate, have a high potential for abuse and dependence. Assess the risk the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
B. Particular attention should be paid to subjects obtaining amphetamines for non-therapeutic use or distribution to others, and the drugs should be described sparingly.
C. Misuse of amphetamine may cause sudden death and serious cardiovascular adverse events.

Strattera®

A. Suicidal ideation in children and adolescents: increases the risk of suicidal ideation in short-term studies in children and adolescents with ADHD. Anyone considering the use in a child or adolescent must balance this risk with the clinical need. Co-morbidities occurring with ADHD may be associated with an increase in the risk of suicidal ideation and/or behavior. Patients who are started on therapy should be monitored closely for suicidality (suicidal thinking and behavior), clinical worsening, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Strattera® is approved for ADHD in pediatric and adult patients. Strattera® is not approved for major depressive disorder. Pooled analyses of short-term (6 to 18 weeks) placebo-controlled trials in children and adolescents (a total of 12 trials involving over 2200 patients, including 11 trials in ADHD and 1 trial in enuresis) have revealed a greater risk of suicidal ideation early during treatment in those receiving Strattera® compared to placebo. The average risk of suicidal ideation in patients receiving Strattera® was 0.4% (5/1357 patients), compared to none in placebo-treated patients (851 patients). No suicides occurred in these trials.

Focalin®, Concerta®, Daytrana® Metadate® CD, Metadate® ER,Methylin®, Ritalin LA®, Methylphenidate ER

A. Drug dependence: should be given cautiously to patients with a history of drug dependence or alcoholism. Chronic, abusive use can lead to marked tolerance and psychological dependence with varying degrees of abnormal behavior. Frank psychotic episodes can occur, especially with parenteral abuse. Careful supervision is required during drug withdrawal from abusive use since severe depression may occur. Withdrawal following chronic therapeutic use may unmask symptoms of the underlying disorder that may require follow-up.

Desoxyn®

A. Methamphetamine has a high potential for abuse. It should thus be tried only in weight reduction programs for patients in whom alternative therapy has been ineffective. Administration of methamphetamine for prolonged periods of time in obesity may lead to drug dependence and must be avoided. Particular attention should be paid to the possibility of subjects obtaining methamphetamine for non-therapeutic use or distribution to others, and the drugs should be prescribed or dispensed sparingly. Misuse of methamphetamine may cause sudden death and serious cardiovascular adverse events.

Antidepressants

Prozac® Weekly™

A. Suicidal thoughts and behaviors: antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increased. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older.

B. In patients of all ages who are started in antidepressant therapy, monitor closely for worsening and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber.
C. Not approved for use in children less than 7 years of age.

Contraceptives

NuvaRing®, Ortho Evra®, Xulane®

A. Cigarette smoking and serious cardiovascular events: cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive (CHC) use. This risk increases with age, particularly in women over 35 years of age and with the number of cigarettes smoked. For this reason, CHCs should not be used by women who are over 35 years of age and smoke.

Ortho Evra®, Xulane®

A. Risk of venous thromboembolism: the risk of VTE among women aged 15-44 who used the patch compared to women who used several different oral contraceptives was assessed in five U.S. epidemiologic studies using electronic healthcare claims data. The relative risk estimates ranged from 1.2 to 2.2; one of the studies found a statistically significant increased relative risk of VTE for current users.
B. Pharmacokinetic profile of ethinyl estradiol: the PK profile for the patch is different from the PK profile for oral contraceptives in that it has a higher steady state concentrations and a lower peak concentration. Area under the time-concentration curve (AUC) and average concentration at steady state (Css) for EE are approximately 60% higher in women than compared with women using an oral contraceptive containing 35 mcg of EE. In contrast, the peak concentration (Cmax) for EE is approximately 25% lower in women using the patch. It is not known whether there are changes in the risk of serious adverse events based on the differences in PK profiles of EE in women using Ortho Evra® compared with women using oral contraceptives containing 30–35 mcg of EE. Increased estrogen exposure may increase the risk of adverse events, including VTE.

Depo-Provera®

A. Loss of bone mineral density: women may lose significant bone mineral density. Bone loss is greater with increasing duration of use and may not be completely reversible.It unknown if use during adolescence or early adulthood, a critical period of bone accretion, will reduce peak bone mass and increase the risk for osteoporotic fracture in later life. It should not be used as a long-term birth control method (i.e., longer than 2 years) unless other birth control methods are considered inadequate.

Migraine Agents

Butorphanol tartrate NS

A. Exposes patients and others to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing and monitor all patients regularly for the development of these behaviors and conditions.
B. Serious, life-threatening, or fatal respiratory depression may occur with use. Monitor for respiratory for respiratory depression, especially during initiation or following a dose increase.
C. Accidental exposure, especially by children, can result in fatal overdose.
D. Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatalogy experts.
E. Interactions with drugs affecting cytochrome P450 isoenzymes: the concomitant use of butorphanol tartrate NS with all cytochrome P450 3A4 inhibitors may result in an increase in butorphanol plasma concentrations, which could increase or prolong adverse reactions and potentially fatal respiratory depression. Discontinuation

of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in butorphanol concentration. The effects of concomitant use or discontinuation of cytochrome P450 3A4 inducers, 3A4 inhibitors, or 2D6 inhibitors with tramadol or codeine are complex and requires careful consideration of the effects on the parent drug and the active metabolite.

F. Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.

Migranal®

A. Serious and/or life-threatening peripheral ischemia has been associated with the co-administration of dihydroergotamine with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP 3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of these medications is contraindicated.

Treximet® (sumatriptan/naproxen)

A. May cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. TREXIMET® is contraindicated in the setting of coronary artery bypass graft.
B. NSAID containing products cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events

Miscellaneous agents

Flector® patch, Zipsor®, Sprix®

A. Cardiovascular thrombotic events: NSAIDs cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. It is contraindicated in the setting of coronary artery bypass graft surgery.
B. Gastrointestinal bleeding, ulceration, and perforation: NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.

Entresto™

A. Fetal toxicity: when pregnancy is detected, discontinue as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.

Xyrem®

A. Central nervous system depression: in clinical trials at recommended doses obtundation and clinically significant respiratory depression occurred in Xyrem®treated patients. Almost all of the patients who received Xyrem® during clinical trials in narcolepsy were receiving central nervous system stimulants.

B. Misuse and abuse: Xyrem® is a sodium salt of gamma hydroxybutyrate (GHB). Abuse of GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death. Because of because of the risks of CNS

depression, abuse, and misuse, it is available only through a restricted distribution program called the Xyrem REMS Program, using the central pharmacy that is specially certified. Prescribers must enroll in the program.

Bevyxxa®

A. Epidural or spinal hematomas may occur in patients treated with betrixaban who are receiving neuraxial anesthesia or undergoing spinal puncture. The risk of these events may be increased by the use of in-dwelling epidural catheters or the concomitant use of medical products affecting hemostasis. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures.

Sedative Hypnotics

Estazolam, Flurazepam HCL, Restoril®, Halcion®

A. Concomitant use of benzodiazepines and opioids: may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and duration to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.

Smoking Cessation Products

Zyban®

A. Suicidality and antidepressant drugs: although it is not indicated for the treatment of depression, it contains the same active ingredient as the antidepressant medication Wellbutrin®. Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects over age 24; there was a reduction in risk with antidepressant use in subjects aged 65 and older. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber.

Guidelines:

Refer to the specific manufacturer's prescribing information for administration and dosage details and any applicable Black Box warnings.

BENEFIT APPLICATION

Subject to the terms and conditions of the applicable benefit contract, the applicable drug(s) identified in this policy is (are) covered under the prescription drug benefits of the Company’s products when the medical necessity criteria listed in this pharmacy policy are met. Any services that are experimental/investigational or cosmetic are benefit contract exclusions for all products of the Company.

References:

AcipHex® (rabeprazole) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc.; June 2018. Accessed November 26, 2018.

AcipHex® Sprinkle™ (rabeprazole) [prescribing information]. Chesterfield, MO: Avadel Pharmaceuticals (USA), Inc.; June 2018. Accessed November 26, 2018.

Actonel® (risedronate sodium) [prescribing information]. Parsippany, NJ: Allergan, Inc; Jan 2018. Accessed November 26, 2018.

Ambien® (zolpidem tartrate) [prescribing information]. Paris, France: Sanofi-Aventis U.S. LLC; September 2018. Accessed November 26, 2018.

Ambien® CR (zolpidem tartrate) [prescribing information]. Paris, France: Sanofi-Aventis U.S. LLC; September 2018. Accessed November 26, 2018.

Adzenys ER® (amphetamine) [prescribing information]. Grand Prairie, TX: Neos Therapeutics; December 2017. Accessed November 26, 2018.

Adzenys XR-ODT™ (amphetamine) [prescribing information]. Grand Prairie, TX: Neos Therapeutics; December 2017. Accessed November 26, 2018.

Adderall® (dextroamphetamine/amphetamine) [prescribing information]. North Wales, PA: Teva Phamaceuticals; July 2018. Accessed November 26, 2018.

Adderall XR® (dextroamphetamine/amphetamine) [prescribing information]. Social Circle, GA: Shire US Manufacturing Inc.; July 2018. Accessed November 26, 2018.

Adrenaclick® (epinephrine) [prescribing information]. Canonsburg, PA: Mylan Pharmaceuticals Inc.; 2017. Accessed November 26, 2018.

Alendronate [prescribing information]. South Beloit, IL: TAGI Pharma, Inc.; 2016. Accessed November 26, 2018.

Amerge® (naratriptan) [prescribing information]. Philadelphia, PA: GlaxoSmithKline LLC; 2016. Accessed November 26, 2018.

Ampyra® (dalfampridine) [prescribing information]. Ardsley, NY: Acorda Therapeutics, Inc.; 2017. Accessed November 26, 2018.

Aptensio XR™ (methylphenidate) [prescribing information]. Coventry, RI: Rhodes Pharmaeuticals; 2017. Accessed November 26, 2018.

Atelvia® (risedronate) [prescribing information]. Parsippany, NJ: Warner Chilcott (US), LLC; 2015. Accessed November 26, 2018.

Auvi-Q® (epinephrine) [prescribing information]. Richmond, VA: Kaleo, Inc.; 2017. Accessed November 26, 2018.

Avonex® (interferon beta-1a) [prescribing information]. Cambridge, MA: Biogen Inc.; 2017. Accessed November 26, 2018.

Axert® (almotriptan) [prescribing information]. Horsham, PA: Janssen Pharmaceuticals, Inc; 2017. Accessed November 26, 2018.

Belsomra® (suvorexant) [prescribing information]. Kenilworth, NJ: Merck Sharp & Dohme Corp; July 2018. Accessed November 26, 2018.

Betaseron® (interferon beta-1b) [prescribing information]. Montville, NJ: Bayer HealthCare Pharmaceuticals Inc.; August 2018. Accessed November 26, 2018.

Bevyxxa® (betrixaban) [prescribing information]. South San Francisco, CA: Portola Pharmaceuticals, Inc.; 2017. Accessed November 26, 2018.

Binosto™ (alendronate) [prescribing information]. San Antonio, TX: Mission Pharmacal Company; 2016. Accessed November 26, 2018.

Boniva® (ibandronate) [prescribing information]. Phoenixville, PA: Genentech, Inc.; 2016. Accessed November 26, 2018.

Bravelle® (urofollitropin) [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals Inc.; 2015. Accessed November 26, 2018.

Butorphanol tartrate NS [prescribing information]. Weston, FL: Apotex Corp.; 2017. Accessed November 26, 2018.

Caverject® (alprostadil) [prescribing information]. Peapack, NJ: Pharmacia and Upjohn Company LLC; 2017. Accessed November 26, 2018.

Chantix® (varenicline) [prescribing information]. Collegeville, PA: Pfizer Laboratories Div Pfizer Inc; June 2018. Accessed November 26, 2018.

Cialis® (tadalafil) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; Feb 2018. Accessed November 26, 2018.

Concerta® (methylphenidate) [prescribing information]. Horsham, PA: Janssen Pharmaceuticals, Inc; 2017. Accessed November 26, 2018.

Copaxone® (glatiramer acetate) [prescribing information]. Isreal: Teva Neuroscience, Inc.; September 2018. Accessed November 26, 2018.

Cresemba® (isavuconazonium) [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc.; April 2018. Accessed November 26, 2018.

Daytrana® patch (methylphenidate) [prescribing information]. New York, NY: Noven Therapeutics, LLC; November 2018. Accessed November 26, 2018.

Denavir® (penciclovir) [prescribing information]. Roseland, NJ: New American Therapeutics, Inc.; 2013. Accessed November 26, 2018.

Depo-Provera® (medroxyprogesterone acetate) [prescribing information]. Peapack, NJ: Pharmacia and Upjohn Company LLC; 2017. Accessed November 26, 2018.

Desoxyn® (methamphetamine HCL) [prescribing information]. Lebanon, NJ: Recordati Rare Diseases, Inc; 2017. Accessed November 26, 2018.

Dexedrine® (dextroamphetamine) [prescribing information]. Horsham, PA: Amedra Pharmaceuticals LLC; 2017. Accessed November 26, 2018.

Dexilant® (dexlansoprazole) [prescribing information]. Lake County, IL: Takeda Pharmaceuticals America, Inc; 2018. Accessed November 26, 2018.

Dextroamphetamine sulfate [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc.; 2015. Accessed November 26, 2018.

Dificid® (fidaxomicin) [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; 2015. Accessed November 26, 2018.

Dyanavel® XR (amphetamine) [prescribing information]. Monmouth Junction, NJ: Tris Pharma Inc; 2017. Accessed November 26, 2018.

Edex® (alprostadil) [prescribing information]. Lake Forest, IL: Actient Pharmaceuticals, LLC; 2015. Accessed November 26, 2018.

Edluar™ (zolpidem tartrate) [prescribing information]. Somerset, NJ: Meda Pharmaceuticals; 2018 Accessed November 26, 2018.

Ella® (ulipristal) [prescribing information]. Charleston, SC: Afaxys Inc.; 2017. Accessed November 26, 2018.

Emend® (aprepitant) [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; 2017. Accessed November 26, 2018.

Emverm® (mebendazole) [prescribing information]. Wilmington, NC: Impax Laboratories, Inc.; 2017. Accessed November 26, 2018.

Entresto™ (sacubutril/valsartan) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2017. Accessed November 26, 2018.

EpiPen® (epinephrine) [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc.; 2018. Accessed November 26, 2018.

Estazolam [prescribing information]. Parsippany, NJ: Actavis Pharma, Inc.; 2016. Accessed November 26, 2018.

Evzio® (naloxone) [prescribing information]. Richmond, VA: Kaleo, Inc.; 2016. Accessed November 26, 2018.

Extavia® (interferon beta-1b) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2016. Accessed November 26, 2018.

Firazyr® (icatibant) [prescribing information]. Exton, PA: Shire US Manufacturing Inc.; 2015. Accessed November 26, 2018.

Flector® patch (diclofenac) [prescribing information]. Collegeville, PA: Pfizer Laboratories Div Pfizer Inc; 2018. Accessed November 26, 2018.

Flurazepam HCL [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc.; 2016. Accessed November 26, 2018.

Focalin® (dexmethylphenidate) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2017. Accessed November 26, 2018.

Focalin XR® (dexmethylphenidate) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2017. Accessed November 26, 2018.

Follistim® AQ (follitropin beta) [prescribing information]. Roseland, NJ: Organon USA Inc.; 2014. Accessed November 26, 2018.

Fosamax® (alendronate) [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; 2016. Accessed November 26, 2018.

Fosamax® Plus D (alendronate) [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; 2016. Accessed November 26, 2018.

Frova® (frovatriptan) [prescribing information]. Malvern, PA: Endo Pharmaceuticals Inc.; 2018. Accessed November 26, 2018.

Gonal-F® (follitropin alpha) [prescribing information]. Billerica, MA: EMD Serono, Inc.; 2018. Accessed November 26, 2018.

Gonsl-F® RFF (follitropin alpha) [prescribing information]. Billerica, MA: EMD Serono, Inc.; 2018. Accessed November 26, 2018.

Halcion® (triazolam) [prescribing information]. Kalamazoo, MI: Pharmacia and Upjohn Company LLC; 2017. Accessed November 26, 2018.

Hetlioz® (tasimelteon) [prescribing information]. Washington, DC: Vanda Pharmaceuticals Inc.; 2014. Accessed November 26, 2018.

Imitrex® (sumatriptan) [prescribing information]. Philadelphia, PA: GlaxoSmithKline LLC; 2017. Accessed November 26, 2018.

Intermezzo® (zolpidem tartrate) [prescribing information]. Stamford, CT: Purdue Pharma LP; 2015. Accessed November 26, 2018.

Intuniv® ER (guanfacine HCL) [prescribing information]. Exton, PA: Shire US Manufacturing Inc.; 2016. Accessed November 26, 2018.

Kapvay™ (clonidine) [prescribing information]. Oaksville, Ontario: Concordia Pharmaceuticals Inc.; 2018. Accessed November 26, 2018.

Levitra® (vardenafil) [prescribing information]. Philadelphia, PA: GlaxoSmithKline LLC; 2017. Accessed November 26, 2018.

Lidoderm® (lidocaine) [prescribing information]. Malvern, PA: Endo Pharmaceuticals Inc.; 2016. Accessed November 26, 2018.

Lunesta® (uneszopiclone) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; 2017. Accessed November 26, 2018.

Lucemyra™ (lofexidine) [prescribing information]. Louisville, KY: US WorldMeds, LLC. Accessed November 26, 2018.

Maxalt® (rizatriptan) [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; 2016. Accessed November 26, 2018.

Maxalt® MLT (rizatriptan) [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; 2016. Accessed November 26, 2018.

Menopur® (menotropins) [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals Inc.; 2018. Accessed November 26, 2018.

Metadate CD® (methyphenidate HCL) [prescribing information]. Rochester, NY: Unither Manufacturing, LLC; 2016. Accessed November 26, 2018.

Metadate® ER (methylphenidate HCL) [prescribing information]. Rochester, NY: Unither Manufacturing, LLC; 2016. Accessed November 26, 2018.

Methylin® (methylphenidate HCL) [prescribing information]. Florham Park, NJ: Shionogi Inc.; 2017. Accessed November 26, 2018.

Migranal® (dihydroergotamine) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2017. Accessed November 26, 2018.

Muse® (alprostadil) [prescribing information]. Somerset, NJ: Meda Pharmaceuticals Inc.; 2018. Accessed November 26, 2018.

MyWay™ (levonorgestrel) [prescribing information]. Somerset, NJ: GAVIS Pharmaceuticals, LLC; 2013. Accessed November 26, 2018.

Narcan® (naloxone nasal spray) [prescribing information]. Radnor, PA: Adapt Pharma, Inc. 2017: Accessed November 26, 2018.

Nexium (esomeprazole magnesium) [prescribing information]. Somerset, NJ: GAVIS Pharmace]. Gaithersburg, MD: AstraZeneca Pharmaceuticals LP; 2018. Accessed November 26, 2018.

Next Choice One Dose® (levonorgestrel) [prescribing information]. Parsippany-Troy Hills, NJ: Actavis Pharma, Inc.; 2014. Accessed November 26, 2018.

Nicotine [prescribing information]. Camp Hill, PA: Rite Aid Corporation; 2016. Accessed November 26, 2018.

Noxafil® (posaconazole) [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; 2017. Accessed November 26, 2018.

NuvaRing® (ethinyl estradiol/ etonogestrel) [prescribing information]. Roseland, NJ: Organon USA Inc.; 2017. Accessed November 26, 2018.

Onzetra™ Xsail™ (sumatriptan nasal powder) [prescribing information]. Aliso Viejo, CA: Avanir Pharmaceuticals, Inc.; 2017. Accessed November 26, 2018.

Plan B One-Step® (levonorgestrel) [prescribing information]. Cincinnati, OH: Teva Women's Health, Inc.; 2016. Accessed November 26, 2018.

Plegridy™ (peginterferon beta 1-a) [prescribing information]. Cambridge, MA: Biogen Inc.; 2017. Accessed November 26, 2018.

Prevacid®revacide, MA: Biogen Inc.; 2017. Accessed August 18, 2017:Takeda Pharmaceuticals America, Inc; 2016. Accessed November 26, 2018.

Prilosec® (omeprazole magnesium) [prescribing information]. Gaithersburg, MD: AstraZeneca Pharmaceuticals LP; 2016. Accessed November 26, 2018.

ProCentra® (dextroamphetamine sulfate) [prescribing information]. Charlotte, NC: FSC Laboratories, Inc; 2010. Accessed November 26, 2018.

Protonix® (pantoprazole sodium) [prescribing information]. Collegeville, PA: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.; 2017. Accessed November 26, 2018.

Prozac® Weekly™ (fluoxetine) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2017. Accessed November 26, 2018.

Prudoxin™ (doxepin) [prescribing information]. Newtown, PA: Prestium Pharma, Inc.; 2015. Accessed November 26, 2018.

Quillichew ER™ (methylphenidate) [prescribing information]. Cupertino, CA: NextWave Pharmaceuticals, Inc.; 2018. Accessed November 26, 2018.

Quillivant XR® (methylphenidate) [prescribing information]. Cupertino, CA: NextWave Pharmaceuticals, Inc.; 2018. Accessed November 26, 2018.

Rebif® (interferon beta-1a) [prescribing information]. Billerica, MA: EMD Serono, Inc.; 2015. Accessed February 13, 2018.

Relenza® (zanamivir) [prescribing information]. Philadelphia, PA: GlaxoSmithKline LLC;2018. Accessed November 26, 2018.

Relpax® (eletriptan) [prescribing information]. Belmont, WA: Roerig; 2016. Accessed November 26, 2018.

Restasis® (cyclosporine) [prescribing information]. Parsippany, NJ: Allergan, Inc; 2017. Accessed November 26, 2018.

Restoril™ (temazepam) [prescribing information]. UK: Mallinckrodt, Inc.; 2016. Accessed November 26, 2018.

Ritalin® (methylphenidate HCL) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2017. Accessed November 26, 2018.

Ritalin LA® (methylphenidate HCL) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2017. Accessed November 26, 2018.

Rozerem® (ramelteon) [prescribing information]. Lake County, IL:Takeda Pharmaceuticals America, Inc; 2010. Accessed November 26, 2018.

Sivextro® (tedizolid phosphate) [prescribing information]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; 2017. Accessed November 26, 2018.

Sonata® (zaleplon) [prescribing information]. Collegeville, PA: Pfizer Laboratories Div Pfizer Inc; 2016. Accessed November 26, 2018.

Sprix® (ketorolac tromethamine) [prescribing information]. Wayne, PA: Egalet US Inc.; 2018. Accessed November 26, 2018.

Staxyn® (vardenafil) [prescribing information]. Philadelphia, PA: GlaxoSmithKline LLC; 2017. Accessed November 26, 2018.

Stendra® (avanafil) [prescribing information]. Cranford, NJ: Mist Pharmaceuticals, LLC; 2018. Accessed November 26, 2018.

Strattera® (atomoxetine) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2017. Accessed November 26, 2018.

Sumavel® (sumatriptan) [prescribing information]. Malvern, PA: Endo Pharmaceuticals Inc.; 2016. Accessed November 26, 2018.

Tamiflu® (oseltamivir) [prescribing information]. Phoenixville, PA: Genentech, Inc.; 218. Accessed November 26, 2018.

Treximet® (sumatriptan/naproxen) [prescribing information]. Philadelphia, PA: GlaxoSmithKline LLC; 2016. Accessed November 26, 2018.

Viagra® (sildenafil) [prescribing information]. Collegeville, PA: Pfizer Laboratories Div Pfizer Inc; 2017. Accessed November 26, 2018.

Vyvanse® (lisdexamphetamine dimesylate) [prescribing information]. Exton, PA: Shire LLC; 2018. Accessed November 26, 2018.

Xulane® (ethinyl estradiol/norelgestromin) [prescribing information]. Mylan Pharmaceuticals Inc.; 2017. Accessed November 26, 2018.

Xyrem® (sodium oxybate) [prescribing information]. Dublin, Ireland: Jazz Pharmaceuticals; 2018. Accessed November 26, 2018.

Zegerid® (omeprazole and sodium bicardbonate) [prescribing information]. San Diego, CA: Santarus, Inc.; 2016. Accessed November 26, 2018.

Zembrace™ SymTouch™ (sumatriptan succinate injection for subcutaneous use) [prescribing information]. Princeton, NJ: Promius Pharma, LLC.; 2017. Accessed November 26, 2018.

Zenzedi™ (dextroamphetamine) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals, Inc.; 2017 Accessed November 26, 2018.

Zipsor® (diclofenac potassium) [prescribing information]. Newark, CA: Depomed, Inc.; 2016. Accessed November 26, 2018.

Zolpimist® (zolpidem tartrate spray) [prescribing information]. Henrico, VA: ECR Pharmaceuticals; 2016. Accessed November 26, 2018.

Zomig® (zolmitriptan) [prescribing information]. Hayward, CA: Impax Specialty Pharma; 2017. Accessed November 26, 2018.

Zomig® ZMT (zolmitriptan) [prescribing information]. Hayward, CA: Impax Specialty Pharma; 2017. Accessed November 26, 2018.

Zonalon® (doxepin) [prescribing information]. Newtown, PA: Prestium Pharma, Inc.; 2015. Accessed November 26, 2018.

Zovirax® (acyclovir cream) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2017. Accessed November 26, 2018.

Zovirax® (acyclovir ointment) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2017. Accessed November 26, 2018.

Zyban® (bupropion HCL) prescribing information]. Philadelphia, PA: GlaxoSmithKline LLC; 2017. Accessed November 26, 2018.

Micromedex. Available at http://www.micromedexsolutions.com/. Accessed November 26, 2018.

Applicable Drugs:

Inclusion of a drug in this table does not imply coverage. Eligibility, benefits, limitations, exclusions, precertification/referral requirements, provider contracts, and Company policies apply.

Medication	Maximum Quantity per day	Quantity limit per rolling 30 days, unless otherwise specified (tablets, capsules, mL)	
ADHD Agents			
Amphetamine (Adzenys XR®)	1	30	
Amphetamine (Adzenys ER®) 1.25mg/ml susp	15 ml	450	
Dextroamphetamine/Amphetamine (Adderall®) 5mg, 7.5mg, 10mg, 12.5mg, 15mg and 20mg	3	90	
Dextroamphetamine/Amphetamine (Adderall®) 30mg	2	60	
Dextroamphetamine/Amphetamine (Adderall XR®) 5mg, 10mg, 15mg, 20mg, 25mg, 30mg	1	30	
Amphetamine (Dyanavel XR®) 2.5mg/ml Susp	8mL	240	
Atomoxetine HCL (Strattera®) 10mg, 18mg, 25mg, 40mg	2	60	
Atomoxetine HCL (Strattera®) 60mg, 80mg, 100mg	1	30	
Clonidine HCL (Kapvay®) 0.1mg	4	120	
Dextroamphetamine sulfate (Dexedrine®) 5mg cap SA	3	90	
Dextroamphetamine sulfate (Dexedrine®) 10mg cap SA	6	180	
Dextroamphetamine sulfate (Dexedrine®) 15mg cap SA	4	120	
Dextroamphetamine sulfate 5mg tablet	3	90	
Dextroamphetamine sulfate 10mg tablet	3	90	
Dexmethylphenidate HCL (Focalin®) 2.5mg, 5mg, 10mg	2	60	
Dexmethylphenidate HCL (Focalin XR®) 5mg, 10mg, 15mg, 20mg, 25mg, 30mg, 35mg, 40mg	1	30	
Dextroamphetamine sulfate (Procentra®) 5mg/5ml solution	60	1800	

Dextroamphetamine (Zenzedi®) 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg tablet	3	90	
Dextroamphetamine (Zenzedi®) 30mg tablet	2	60	
Guanfacine HCL (Intuniv ER®) 1mg, 2mg, 3mg, 4mg tablet	1	30	
Lisdexamfetamine dimesylate (Vyvanse®) 20mg, 30mg, 40mg, 50mg, 60mg, 70mg	1	30	
Methylphenidate (Aptensio XR®)	1	30	
Methylphenidate HCL (Concerta®) 18mg, 27mg, 54mg	1	30	
Methylphenidate HCL (Concerta®) 36mg tablet ER	2	60	
Methylphenidate HCL ER 72mg osmotic release tab	1	30	
Methylphenidate (Daytrana patch®) 10mg/9hr, 15mg/9hr, 20mg/9hr, 30mg/9hr	1	30	
Methamphetamine HCL (Desoxyn®) 5mg tablet	5	150	
Methylpenidate HCL (Metadate CD®) 10mg, 20mg, 30mg, 40mg, 50mg, 60mg	1	30	
Methylphenidate HCL (Metadate ER®) 10mg, 20mg tablet SA	3	90	
Methylphenidate HCL (Methylin®) 2.5mg, 10mg chewable tablet	6	180	
Methylphenidate HCL (Methylin®) 5mg chewable tablet	3	90	
Methylphenidate HCL (Methylin®) 10mg/5ml	30	900	
Methylphenidate HCL (Methylin®) 5mg/5ml	60	1800	
Methylphenidate HCL (Ritalin®) 5mg, 10mg, 20mg	3	90	
Methylphenidate HCL (Ritalin LA®) 10mg, 40mg capsule	1	30	
Methylphenidate HCL (Ritalin LA®) 20mg capsule	3	90	

Methylphenidate HCL (Ritalin LA®) 30mg capsule	2	60	
Methylphenidate (Quillichew ER®) 20mg, 30mg	2	60	
Methylphenidate (Quillichew ER®) 40mg	1	30	
Methylphenidate (Quillivant XR®) 5mg/mL	12mL	360	
Methylphenidate ER disintegrating tabs (Cotempla®) 8.6mg, 17.3mg, 25.9mg	1	30	
Antiemetics			
Aprepitant (Emend®) 80mg	NA	8	
Aprepitant (Emend®) 40mg	NA	2	
Aprepitant (Emend®) 125mg	NA	4	
Aprepitant (Emend®) trifold pack	NA	4 packs	
Antidepressant			
Fluoxetine (Prozac weekly®)	NA	4	
Antivirals/Antiinfectives			
Mebendazole (Emverm®)	NA	6/21 days	
Fidaxomicin (Dificid®)	NA	20/10 days	
Isavuconazonium (Cresemba®) capsule	NA	68	
Oseltamivir (Tamiflu®) 6mg/ml	NA	180mL (3 bottles) per Rx	
Oseltamivir (Tamiflu®) 30mg	NA	20 perRx	
Oseltamivir (Tamiflu®) 45mg, 75mg	NA	10 perRx	
Posaconazole (Noxafil®) 100mg tab	NA	93	
Tedizolid phosphate (Sivextro®)	NA	6 per 6 days	
Penciclovir (Denavir®)	NA	5 grams	
Zanamivir (Relenza®)	NA	1 Diskhaler per Rx	
Rifaximin (Xifaxan 200mg)	NA	9/ 90days	
Acyclovir cream (Zovirax®)	NA	5g	
Acyclovir ointment (Zovirax®)	NA	30g	
Bowel Prep Kits			
Peg 3350-electrolyte (Nulytely, Trilyte, Golytely, Colyte)	NA	2 kits/year (8000ml)	

Peg-prep kits	NA	2 kits/year	
Contraceptives			
Diaphragm	NA	1 per year	
Ethinyl estradiol/etonogestrel (Nuvaring®)	NA	1per 28 days	
Ethinyl estradiol/norelgestromine (Ortho Evra®, Xulane patch®)	NA	3	
Female condoms	NA	15	
Levonorgestrel 1.5mg (My Way®, Next Choice®, One Dose®, Plan B one-step®)	NA	3	
Medroxyprogesterone acetate (Depo-Provera®)	NA	1 per 90 days	
Ulipristal (Ella®)	NA	3	
Diabetic Supplies/Drugs			
Blood glucose monitor	NA	2 per year	
Diabetic test strips	NA	200	
Insulin injecting device (e.g. Novopen®)	NA	2per year	
Insulin syringes and pen needles	NA	200	
Lancets	NA	200	
Insulin products	2mL	60	
Erectile Dysfunction			
Alprostadil (Caverject®, IFE-PG20)	NA	8	
Alprostadil (Edex®, Muse®)	NA	8	
Avanafil (Stendra®)	NA	8	
Sildenafil (Viagra®)	NA	8	
Tadalafil (Cialis®) 2.5mg, 5mg	1	30	
Tadalafil (Cialis®) 10mg, 20mg	NA	8	
Vardenafil (Levitra®, Staxyn®)	NA	8	
Injectable Fertility			
Urofollitropin (Bravelle®) 75 unit vial	NA	60	
Follitropin Beta (Follistim AQ®) 75 unit vial	NA	60	
Follitropin Beta (Follistim AQ®) 150 unit vial	NA	30	
Follitropin Beta (Follistim AQ®) 300 unit cartridge	NA	15	

Follitropin Beta (Follistim AQ®) 600 unit cartridge	NA	8	
Follitropin Beta (Follistim AQ®) 900 unit cartridge	NA	5	
Follitropin Alfa (Gonal-F®) 450 units vial	NA	10	
Follitropin Alfa (Gonal-F®) 1050 units vial	NA	5	
Follitropin Alfa (Gonal-F RFF®) 300/0.5ml pen injector	NA	15	
Follitropin Alfa (Gonal-F RFF®) 450/0.75ml pen injector	NA	10	
Follitropin Alfa (Gonal-F RFF®) 900/1.5ml pen injector	NA	5	
Follitropin Alfa (Gonal-F RFF®) 75 unit vial	NA	60	
Menotropins (Menopur®, Repronex®) 75 units vial	NA	60	
Migraine Agents			
Almotriptan (Axert®) 6.25mg	NA	12	
Almotriptan (Axert®) 12.5mg	NA	12	
Eletriptan (Relpax®) 20mg, 40mg	NA	12	
Butorphanol nasal spray	NA	10	
Dihydroergotamine (Migranal®)	NA	8	
Frovatriptan (Frova®) 2.5mg	NA	18	
Naratriptan (Amerge®) 1mg, 2.5mg	NA	9	
Rizatriptan (Maxalt® and Maxalt MLT®) 5mg and 10mg	NA	12	
Sumatriptan (Imitrex®) 4mg injections	NA	14 kits (28 injections)	
Sumatriptan (Imitrex®) 6mg injections	NA	9 kits (18 injections)	
Sumatriptan (Imitrex®) 5mg/actuation nasal spray	NA	36	
Sumatriptan (Imitrex®) 20mg/actuation nasal spray	NA	18	
Sumatriptan (Imitrex®) 6mg/0.5ml subcutaneous cartridge/pen injection	NA	9ml	

Sumatriptan (Imitrex®) 4mg/0.5ml subcutaneous cartridge/pen injection	NA	14ml	
Sumatriptan (Imitrex®) 25mg, 50mg, 100mg	NA	18	
Sumatriptan (Sumavel®)	NA	9ml	
Sumatriptan (Onzetra Xsail®) nasal	NA	16	
Sumatriptan/Naproxen (Treximet®) 85mg/500mg	NA	18	
Sumatriptan (Zembrace symtouch®) 3mg/0.5mL	NA	8	
Zolmitriptan (Zomig®, Zomig ZMT®) 2.5mg, 5mg	NA	9	
Zolmitriptan (Zomig®) 2.5mg, 5mg nasal spray	NA	9	
Miscellaneous			
Cyclosporine (Restasis®)	2	60	
Diclofenac (Flector®) patch	2	60	
Diclofenac potassium (Zipsor®)	4	120	
Doxepin 5% cream (Prudoxin®, Zonalon®)	NA	45g/ 90 days	
Epinephrine pens/auto-injectors (Epi-Pen®, Adrenaclick®, Auvi-Q®)	NA	3 twin packs (6 injections) per 180 days	
Icatibant (Firazyr® 30mg/3ml syringe)	NA	27mL	
Ketorolac tromethamine (Sprix®)	NA	5	
Lidocaine (Lidoderm®) patch	3	90	
Naloxone (Evzio®)	NA	4 (1.6mL)	
Naloxone (Narcan®)	NA	6	
Sacubitril/valsartan (Entresto®)	2	60	
Sodium oxybate (Xyrem®)	18	540	
Betrixaban (Bevyxxa®)	NA	42 days' supply/180 days	
Lofexidine (Lucemyra™)	16	480	
Multiple sclerosis agents			
Dalfampridine (Ampyra®)	2	60	
Interferon beta-1a (Avonex®)	NA	4	

Interferon beta-1a (Rebif/Rebif Rebidose®)	NA	12	
Interferon beta-1b (Betaseron®)	NA	15	
Interferon beta-1b (Extavia®)	NA	15	
Glatiramer acetate (Copaxone® 20mg)	1	30	
Glatiramer acetate (Copaxone® 40mg)	NA	12	
Peginterferon beta-1a (Plegridy®)	NA	1mL per 28 days	
Osteoporosis Agents			
Alendronate 70mg/75ml solution	NA	300mL per 28 days	
Alendronate (Fosamax® and Binosto®) 35mg, 70mg	NA	4 per 28 days	
Alendronate with Vitamin D (Fosamax plus D®) 70mg/2.8ml, 70mg/5.6ml	NA	4 per28 days	
Ibandronate (Boniva®) 150mg	NA	1	
Risedronate sodium (Actonel® and Atelvia®) 35mg	NA	4 per28 days	
Risedronate sodium (Actonel®) 150mg	NA	1 per30 days	
Proton Pump Inhibitor			
Dexlansoprazole (Dexilant®)	2	60	
Esomeprazole magnesium (Nexium®) and strontium capsules	2	60	
Esomeprazole magnesium (Nexium®) packet	1	30	
Lansoprazole (Prevacid®)	2	60	
Lansoprazole (Prevacid®) solu-tab	1	30	
Omeprazole (Prilosec®)	2	60	
Omeprazole/sodium bicarbonate (Zegerid®) packets	1	30	
Pantoprazole sodium (Protonix®)	2	60	
Pantoprazole sodium (Protonix®) packet	1	30	
Rabeprazole (Aciphex®)	2	60	
Rabeprazole (Aciphex®) sprinkle	1	30	
Sedative Hypnotics			
Estazolam	1	30	

Eszopiclone (Lunesta®) 1mg	2	60	
Eszopiclone (Lunesta®) 2mg, 3mg	1	30	
Flurazepam HCL	1	30	
Ramelteon (Rozerem®)	1	30	
Suvorexant (Belsomra®)	1	30	
Tasimelteon (Hetlioz®)	1	30	
Temazepam (Restoril®)	1	30	
Triazolam (Halcion®)	1	30	
Zaleplon (Sonata®)	1	30	
Zolpidem (Zolpimist®)	NA	7.7ml (1 pump)	
Zolpidem tartrate (Ambien®, Ambien CR®, Edluar®, Intermezzo®)	1	30	
Smoking Cessation Products			
Bupropion HCL (Zyban®)	2	60	180 cumulative days' supply per 365 days
Nicotine gum/inhaler/lozenges	10	300	
Nicotine patches	1	30	
Varenicline (Chantix®)	2	60	

Cross References:

Diclofenac Products Rx.01.155

Dalfampridine (Ampyra) Rx.01.122
Epinephrine Pen Policy Rx.01.142
Erectile Dysfunction Agents Rx.01.29
Off-Label Use Policy Rx.01.33

Heart Failure Agents Rx.01.174

Insulin, human U-500 (Humulin R U-500)
Hereditary Angioedema Agents Rx.01.109
Migraine Agents Rx.01.56

Naloxone Auto-injector (Evzio®) Rx.01.167

Opioid policy Rx.01.197
Oral Anti-infective Agents Rx.01.66

Prior Authorization of Select Nonpreferred Drugs Rx.01.202
Proton Pump Inhibitors Rx.01.75
Sleep Agents Rx.01.84
Sodium oxybate (Xyrem®) Rx.01.124

Policy Version Number:	25.00
P&T Approval Date:	April 25, 2019
Policy Effective Date:	May 15, 2019
Next Required Review Date:	October 11, 2019